NFKB1 and Alzheimer disease: It is widely acknowledged that deregulated NF-κB signaling may contribute to acute neurodegenerative conditions, such as cerebral ischemia and traumatic brain injury (Harari and Liao, 2010) as well as chronic neurodegenerative disorders, such as Alzheimer's disease (Jones and Kounatidis, 2017), Parkinson's disease (Flood et al., 2011), Huntington's disease (Bečanović et al., 2015), and ALS (Sako et al., 2012).